Further evaluation of GBA1 and LRRK2 variants and clinical presentation, as well as investigations into interactions between the two genes, is needed to develop biomarkers for early diagnosis and intervention and treatment of PD. The gene discussed is LRRK2; the disease is Parkinson disease.